Treatment of Covid-19 With a Herbal Compound, Xagrotin

Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin

This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361). Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.

This is an interventional, multi-center, randomized study that has been performed in an outpatient setting (n=361). Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited. Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome. Adverse events were registered.

Inclusion Criteria:

• Age 18 or higher
• Newly diagnosed (no longer than 10 days)
• PCR or clinically confirmed Covid-19

Exclusion Criteria:

• Severe pulmonary disease
• Severe cardiovascular disease
• Severe hepatic disease
• Severe renal disease
• Diabetes mellitus type one
• Metabolic acidosis
• Oxygen saturation <70%
• Pregnancy
• Breast feeding
• Concomitant treatment with anticoagulation drugs
• Concomitant treatment with CYP3A4 medicines with narrow therapeutic window